JP2023500385A5 - - Google Patents
Info
- Publication number
- JP2023500385A5 JP2023500385A5 JP2022526767A JP2022526767A JP2023500385A5 JP 2023500385 A5 JP2023500385 A5 JP 2023500385A5 JP 2022526767 A JP2022526767 A JP 2022526767A JP 2022526767 A JP2022526767 A JP 2022526767A JP 2023500385 A5 JP2023500385 A5 JP 2023500385A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019117155 | 2019-11-11 | ||
| CNPCT/CN2019/117155 | 2019-11-11 | ||
| PCT/CN2020/128083 WO2021093764A1 (en) | 2019-11-11 | 2020-11-11 | Pharmaceutical combination and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023500385A JP2023500385A (ja) | 2023-01-05 |
| JP2023500385A5 true JP2023500385A5 (https=) | 2023-11-20 |
Family
ID=75911807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526767A Pending JP2023500385A (ja) | 2019-11-11 | 2020-11-11 | 医薬組合せ物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220387417A1 (https=) |
| EP (1) | EP4031179A4 (https=) |
| JP (1) | JP2023500385A (https=) |
| KR (1) | KR20220103961A (https=) |
| CN (1) | CN114901309A (https=) |
| AU (1) | AU2020383580A1 (https=) |
| BR (1) | BR112022009042A2 (https=) |
| CA (1) | CA3160526A1 (https=) |
| IL (1) | IL292646A (https=) |
| MX (1) | MX2022005034A (https=) |
| WO (1) | WO2021093764A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3515938T (pt) * | 2016-09-21 | 2025-04-10 | Cstone Pharmaceuticals Shanghai Co Ltd | Anticorpos monoclonais contra morte programada 1 (pd-1) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102675282B (zh) * | 2011-03-15 | 2014-12-24 | 广东东阳光药业有限公司 | 取代的喹啉化合物及其使用方法和用途 |
| TWI664977B (zh) * | 2013-10-08 | 2019-07-11 | 第一三共股份有限公司 | 抗ｆｇｆｒ２抗體及其與其他藥劑之組合 |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| KR102662228B1 (ko) * | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| CN106432501B (zh) * | 2015-08-06 | 2021-07-30 | 基石药业 | 新型抗pd-l1抗体 |
| CA3010862A1 (en) * | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
| CN114456269A (zh) * | 2016-09-21 | 2022-05-10 | 基石药业（苏州）有限公司 | 一种新的pd-1单克隆抗体 |
| PT3515938T (pt) * | 2016-09-21 | 2025-04-10 | Cstone Pharmaceuticals Shanghai Co Ltd | Anticorpos monoclonais contra morte programada 1 (pd-1) |
| KR20210122319A (ko) * | 2017-04-06 | 2021-10-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 비스-링키지를 사용한 세포독성 약물의 접합 |
| CA3060514A1 (en) * | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| CN109988112A (zh) * | 2017-12-29 | 2019-07-09 | 四川科伦药物研究院有限公司 | 仑伐替尼甲磺酸盐的晶型及其制备方法 |
| CN108379591B (zh) * | 2018-04-03 | 2022-03-29 | 深圳大学 | 免疫激动剂靶向化合物的合成及其应用 |
| CN109731019B (zh) * | 2019-03-07 | 2021-07-16 | 康赋葆(深圳)生物医药科技有限公司 | 一种具有化疗增效作用的组合物，包括组成、制备及应用 |
| CN109867626A (zh) * | 2019-04-18 | 2019-06-11 | 安礼特（上海）医药科技有限公司 | 一种甲磺酸仑伐替尼多晶型物及其制备方法 |
-
2020
- 2020-11-11 KR KR1020227017523A patent/KR20220103961A/ko not_active Ceased
- 2020-11-11 WO PCT/CN2020/128083 patent/WO2021093764A1/en not_active Ceased
- 2020-11-11 JP JP2022526767A patent/JP2023500385A/ja active Pending
- 2020-11-11 CN CN202080078664.3A patent/CN114901309A/zh active Pending
- 2020-11-11 AU AU2020383580A patent/AU2020383580A1/en active Pending
- 2020-11-11 MX MX2022005034A patent/MX2022005034A/es unknown
- 2020-11-11 US US17/776,179 patent/US20220387417A1/en active Pending
- 2020-11-11 EP EP20888069.0A patent/EP4031179A4/en not_active Withdrawn
- 2020-11-11 BR BR112022009042A patent/BR112022009042A2/pt unknown
- 2020-11-11 CA CA3160526A patent/CA3160526A1/en active Pending
-
2022
- 2022-05-01 IL IL292646A patent/IL292646A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7401126B2 (ja) | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 | |
| KR102905497B1 (ko) | 항체-약물 컨쥬게이트와 parp 저해제의 조합 | |
| JP2023509196A5 (https=) | ||
| JP2024037894A5 (https=) | ||
| JP2020528750A5 (https=) | ||
| JP2020502271A5 (https=) | ||
| TW202019487A (zh) | 抗體-藥物結合物及微管蛋白抑制劑之組合 | |
| JP2019532056A5 (https=) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| JP2010535713A5 (https=) | ||
| JP2017514795A5 (https=) | ||
| TW202210507A (zh) | 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途 | |
| RU2020115713A (ru) | Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения | |
| EP3186278A1 (en) | Internalizing moieties for treatment of cancer | |
| TW202537975A (zh) | 抗體－藥物結合物之製造方法 | |
| TW202214691A (zh) | 抗-egfr抗體及抗體藥物結合物 | |
| RU2006132466A (ru) | Высококонцентрированные жидкие композиции анти-egfr антител | |
| EP4523704A1 (en) | Camptothecin derivative and ligand-drug conjugate | |
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2019524714A5 (https=) | ||
| JP2024535930A5 (https=) | ||
| JP2025509266A5 (https=) | ||
| JP2024504331A5 (https=) | ||
| JP2023500385A5 (https=) |